Burning Rock Biotech Ltd
NASDAQ:BNR
Burning Rock Biotech Ltd
Cash Equivalents
Burning Rock Biotech Ltd
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Burning Rock Biotech Ltd
NASDAQ:BNR
|
Cash Equivalents
¥615.1m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash Equivalents
¥1.4B
|
CAGR 3-Years
92%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Burning Rock Biotech Ltd's Cash Equivalents?
Cash Equivalents
615.1m
CNY
Based on the financial report for Dec 31, 2023, Burning Rock Biotech Ltd's Cash Equivalents amounts to 615.1m CNY.
What is Burning Rock Biotech Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
46%
Over the last year, the Cash Equivalents growth was -32%. The average annual Cash Equivalents growth rates for Burning Rock Biotech Ltd have been -31% over the past three years , 46% over the past five years .